Business
Allarity Therapeutics to Present at Biomarkers Europe 2023
Allarity will present on development of several drug-specific DRP® companion diagnostics, and participate in a panel discussion with speakers from Merck and
About this update from Allarity Therapeutics, Inc.
[{"type":"text","content":" Allarity will present on development of several drug-specific DRP® companion diagnostics, and participate in a panel discussion with speakers from Merck and Roche BOSTON, October 2, 2023 — Allarity Therapeutics, Inc. (Allarity or the Company) (Nasdaq: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized cancer care, is pleased to announce that the Company has been invited to give a presentation at Biomarkers Europe 2023. The presentation will focus on Allarity’s development of drug-specific DRP® companion diagnostics (CDx) for oncology therapeutics, featuring clinical validation for several exemplary DRP® CDx. Presentation details include: Event: Biomarkers Europe 2023Presentation title: A Gene Expression Based Biomarker for Predicting Response to Treatment with Dovitinib and with IxabepiloneDate: November 14-15, 2023Location: Berlin, GermanyWeb: https://www.oxfordglobal.co.uk/biomarkers-europe/ In addition to its presentation, Allarity is honored to participate in a panel discussion titled \"Prediction Of Drug Response Using An Ex Vivo Organ Culture (EVOC) On Oncology Patients, Clinical Trial Development And Patient Testing\" at the same conference. This panel discussion will be moderated by Jonathan Krell, Clinical Senior Lecturer at Imperial College London, and will feature esteemed panelists: Anna Maria Lara Coenen-Stass, Associate Director, Merck KGaAThomas Jensen, Co-Founder, Allarity TherapeuticsPriscila Teixeira, Head of Biomarker, Bioanalytic and Biosample Office, Roche The Company will also attend the upcoming ThinkEquity Conference in October in New York:https://www.think-equity.com/thinkequity-conference Allarity representatives will be available for one-on-one meetings to discuss business development opportunities. The Company invites attendees to schedule one-on-one meetings in advance. About Allarity Therapeutics Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP® platform. The Company has a mature portfolio of three drug candidates: stenoparib, a PARP inhibitor in Phase 2 development for ovarian cancer, and in Phase 1 development for advanced solid tumors in a combination treatme...